Tesamorelin: What Researchers Need to Know About the Stabilized GHRH Analog
Research overview of Tesamorelin: 16 years of RCT evidence (Falutz NEJM 2007, Stanley Lancet HIV 2019, Baker Arch Neurol 2012, Ellis 2025).
Among synthetic growth hormone secretagogues, Tesamorelin holds a unique regulatory position. It is the only GHRH analog ever to receive full FDA approval (as EGRIFTA in 2010), and the only GHRH-class peptide with pivotal Phase III randomized trials against placebo in indications ranging from visceral fat reduction to non-alcoholic fatty liver disease and mild cognitive impairment. For researchers sourcing Tesamorelin, this 16-year clinical history means something rare: a peptide whose background chemistry, pharmacokinetics and endpoints have been rigorously characterised in peer-reviewed literature.
Modified GHRH analog for lipodystrophy and metabolic liver research
Background: GHRH Biology and the Tesamorelin Modification
Growth Hormone Releasing Hormone (GHRH) is a 44-amino-acid hypothalamic peptide that binds the GHRH receptor on somatotrope cells of the anterior pituitary, triggering pulsatile release of endogenous growth hormone. Native GHRH(1-44) is rapidly inactivated by dipeptidyl peptidase-4 (DPP-4) at its N-terminus, resulting in a plasma half-life measured in minutes - too short for practical research or clinical use.
Tesamorelin is a stabilised analog of human GHRH(1-44). Its structural modification is a trans-3-hexenoyl group attached to the N-terminal tyrosine. This hexenoyl cap protects the peptide from DPP-4 cleavage without altering the receptor-binding pharmacophore. The result is a GHRH analog that preserves the pulsatile, physiological pattern of GH release, rather than producing the sustained, supraphysiological elevation seen with exogenous recombinant GH.
This matters for interpretation: Tesamorelin studies consistently report IGF-1 elevations within or close to the normal physiological range, whereas direct GH administration (Rudman 1990 and successors) routinely produces supraphysiological IGF-1 and the associated adverse-event profile of fluid retention, arthralgia and carpal tunnel syndrome.
What the Research Shows: 16 Years of RCTs
Visceral Fat Reduction
The pivotal Phase III trial (Falutz et al., NEJM 2007) established Tesamorelin as the first and only peptide therapy with approved indication for HIV-associated lipodystrophy with excess abdominal fat. The subsequent pooled analysis (Falutz et al., JCEM 2010, n=806) remains the largest controlled dataset for any GHRH analog. Over 52 weeks, 2 mg/day subcutaneous Tesamorelin reduced visceral adipose tissue (VAT) by approximately 35 cm² relative to placebo, with responders defined as those achieving at least 8% VAT reduction (Stanley et al., CID 2012).
Hepatic Fat and NAFLD
A 2019 double-blind RCT published in The Lancet HIV (Stanley et al., NCT02196831) extended Tesamorelin research to non-alcoholic fatty liver disease (NAFLD/MASH) in the HIV population. In 61 HIV-positive participants with hepatic fat fraction at least 5%, 2 mg/day for 12 months reduced liver fat by 4.1 percentage points absolute, a 37% relative reduction. Strikingly, 35% of Tesamorelin recipients reached the sub-5% threshold that defines resolution of steatosis.
Cognition and MCI
Baker et al. (Arch Neurol 2012, PMID 22869065) randomised older adults with mild cognitive impairment (MCI) and healthy controls to Tesamorelin or placebo for 20 weeks. The trial reported modest but statistically detectable improvements in executive function (effect size 0.03 to 0.002 across measures) and a 117% increase in serum IGF-1. A follow-up MR-spectroscopy analysis (Friedman et al., JAMA Neurol 2013, PMID 23689947) found that GHRH administration increased brain GABA levels and reduced myo-inositol - a pattern of interest in neurodegeneration research.
The picture is more mixed in the most recent trial. Ellis et al. (2025, J Infect Dis, PMID 39813152) conducted a Phase II open-label neurocognitive trial in HIV-associated cognitive complaints (n=73, 2 mg/day for 6 months). The primary analysis reported a trend toward improvement but missed conventional significance (P=.060, between-group). This is an honest null-or-near-null result and should be read as such.
16 Years of Controlled Evidence
Falutz 2007/2010: n=806 pooled, VAT -35 cm² at week 52 vs placebo. Stanley 2019 (Lancet HIV): hepatic fat -4.1 percentage points absolute, 35% reached <5% threshold. Baker 2012: modest executive function improvements, IGF-1 +117% in MCI cohort. Ellis 2025: neurocognitive trend, between-group P=.060 - no significant difference. Friedman 2013: GHRH elevated brain GABA on MR spectroscopy.
Muscle Quality
Post-hoc imaging analyses from the Tesamorelin programme (Adrian et al., J Frailty Aging 2019, PMID 31237318) quantified changes in muscle density of the rectus abdominis and psoas, both markers used in sarcopenia research. The data suggest that GHRH-driven IGF-1 elevation modestly improves muscle attenuation on CT, independently of visceral fat changes.
Quality Criteria When Sourcing Tesamorelin
Tesamorelin synthesis is chemically non-trivial. The trans-3-hexenoyl modification at the N-terminus must be installed with correct stereochemistry, and the 44-residue chain is long enough that truncation, deletion and aspartimide side products are common if synthesis and purification controls are weak.
Purity Testing
Research-grade Tesamorelin should show HPLC purity of at least 98%. At PeptidesDirect, each batch is independently verified by Janoshik Analytical. A complete Certificate of Analysis includes HPLC purity, mass spectrometry confirming the 5196 Da monoisotopic mass, peptide content by nitrogen or UV, and residual solvent and counterion data.
Storage
Tesamorelin is supplied as lyophilised powder. Store at -20 °C before reconstitution; the hexenoyl-stabilised N-terminus is relatively robust in powder form. After reconstitution, store at 2-8 °C, protected from light, and use within 2-4 weeks. Tesamorelin is photosensitive and sensitive to repeated freeze-thaw cycles - aliquot the working solution if protocols extend beyond two weeks.
EU shipping: For European researchers, PeptidesDirect ships from within the EU. No customs, no import fees, delivery in two to three working days with tracking.
Reconstitution
Regulatory Context
Tesamorelin (as EGRIFTA) received FDA approval in 2010 for reduction of excess abdominal fat in HIV-associated lipodystrophy. The European Medicines Agency approved EGRIFTA in 2014 for the same indication, but the product was withdrawn from the EU market in 2020 for commercial rather than safety reasons. In the United States, a new formulation (F8 / EGRIFTA WR) received FDA approval in 2025.
Tesamorelin is listed under WADA S2 (Peptide Hormones, Growth Factors and Related Substances) as a prohibited substance at all times in competitive sport.
In the European Union, Tesamorelin is not currently available as an authorised medicinal product. It is supplied exclusively as a reference compound for in vitro and preclinical research. It is not a medication, not for human consumption, and not intended for diagnostic or therapeutic use.
Among the entire class of GH-axis peptides (Sermorelin, CJC-1295, Ipamorelin, GHRP-2, GHRP-6, Hexarelin), Tesamorelin remains the only compound with a pivotal Phase III dataset, full FDA approval, and over 800 patients in pooled randomised controlled analysis. That makes it the reference peptide for the GHRH-analog class, and an unusually well-characterised research tool.